2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Journal
JACC: Asia
Journal Volume
1
Journal Issue
2
Pages
129 - 146
Date Issued
2021-09-01
Author(s)
Chiang, Chern En
Ueng, Kwo Chang
Chao, Ting Hsing
Lin, Tsung-Hsien
Wu, Yih Jer
Wang, Kang Ling
Sung, Shih Hsien
Yeh, Hung I.
Li, Yi Heng
Liu, Ping Yen
Chang, Kuan Cheng
Shyu, Kou Gi
Huang, Jin Long
Tsai, Cheng Dao
Hung, Huei Fong
Liu, Ming En
Chao, Tze Fan
Cheng, Shu Meng
Cheng, Hao Min
Chu, Pao Hsien
Yin, Wei Hsian
Lai, Wen Ter
Lin, Shing Jong
Yeh, San Jou
Hou, Charles Jia Yin
Abstract
Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.
Subjects
antidiabetic agents | chronic kidney disease | heart failure | Taiwan Society of Cardiology | type 2 diabetes
Type
review